Paediatric galenics: a challenge and an opportunity proposed by A.P.P.A.® Project for Developing Countries

Francesca Baratta
Non-profit organization Aid Progress Pharmacist Agreement®, Turin, Italy

Department of Scienza e Tecnologia del Farmaco, University of Turin, Italy
“... the Primary Health Care... forms an integral part both of the country’s health system, of which it is the central function and main focus, and of the overall social and economic development of the community. It is the first level of contact... with the national health system, bringing health care as close as possible to where people live and work, and constitutes the first element of a continuing health care service...”

TODAY?
As a result, medicines regulation was not carried out to the full extent required to ensure the quality, efficacy and safety of medicines in African countries. The findings confirm the results of a 2004 questionnaire survey conducted by WHO in 38 African member states, which found that 90% of countries did not provide or enforce adequate regulatory functions.
Countries with a critical shortage of health service providers (doctors, nurses and midwives)

The World Health Report 2006 - working together for health
Chapter 1: Health workers: a global profile
«...water-borne diseases are not caused by lack of antibiotics but by 
**dirty water**, and by the political, social, and economic forces that fail to 
make clean water available to all; heart disease is caused not by a lack 
of coronary care units but by the **lives people lead**, which are shaped 
by the environments in which they live; obesity is not caused by moral 
failure on the part of individuals but by the excess availability of high-fat 
and high-sugar foods ...»

“Closing the gap in a generation: Health equity through action on the 
social determinants of health” – WHO Commission on Social 
Determinants of Health - 2008
Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford.

**BUT...**

- More than fifty percent of the population in the Region have no regular access to essential medicines.
- Medicine supply and regulatory systems are weak
- Financial as well as human resources are inadequate to ensure delivery of pharmaceutical services and ensure access to essential medicines.
- Circulation of poor quality medicines, high medicine prices, unethical promotion and irrational use of medicines poses additional challenges.
A counterfeit medicine is one which is **deliberately and fraudulently mislabeled with respect to identity and/or source.** Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the **correct ingredients** or with the **wrong ingredients**, **without active ingredients**, with **insufficient active ingredients** or with **fake packaging**.

**COUNTERFEIT MEDICINES**

**“IMPERFECT” COUNTERFEITS**

«**these products contain the right components, with an incorrect concentration and/or formulation resulting in defective quality specifications. In the vast majority of cases, they are devoid of any therapeutic efficacy**»

**“CRIMINAL” COUNTERFEITS**

«**they are apparently similar to the original medicinal product, but do not contain any active ingredient and can even include harmful or toxic substances. They are usually sold at high prices and for the treatment of serious pathologies. Consequences for users of criminal counterfeits can be fatal**»

Di Giorgio D. Counterfeit drugs. The phenomenon and enforcement activities. Milano: Tecniche nuove; 2010.
Diffusion of counterfeit drugs in developing Countries and stability of galenics stored for months under different conditions of temperature and relative humidity

F. Baratta, A. Germano, P. Brusa

Diffusion of counterfeit drugs in developing countries and stability of galenics stored for months under different conditions of temperature and relative humidity

CAMEROUN 2012

- Criminal counterfeit: 3%
- Idoneous: 65%
- Imperfect counterfeit: 32%

CAMEROUN 2013

- Criminal counterfeit: 16%
- Idoneous: 47%
- Imperfect counterfeit: 37%

PHARMACEUTICAL FORMS TESTS (Ph Eur)
- Uniformity of content (2.9.6)
- Uniformity of mass (2.9.5)
- Disintegration (2.9.1)
- Friability (2.9.7)
- Hardness (2.9.8)
- Sterility (2.6.1)
CAMEROUN 2013

- Population: 20 million
- Pharmacies on the national territory: 331
- Yaoundé+Douala: 81 pharmacies

HOW MANY ARE THE STREET VENDORS?

PRELIMINARY RESULTS:
- 1047 FAMILIES LIVING IN YAOUNDÉ: THE 99.6%, EVEN IF SCHOOLED, BUY MEDICINAL PRODUCTS BY STREET VENDORS
- THE 34% OF SUBJECTS IS AWARE OF THE RISKS. THE 60% BUY THESE PRODUCTS DUE TO FINANCIAL DIFFICULTIES
- 74 STREET VENDORS HAVE BEEN INTERVIEWED: THE 80% IS MEDIUM-HIGH CULTURAL GRADE
A.P.P.A.® PROJECT
PLANNING, CARRYING OUT, STARTING LABS IN ORDER TO PREPARE GALENIC MEDICINAL PRODUCTS AND RELATIVE QUALITY CONTROL IN DEVELOPING COUNTRIES

With the patronage of:

Università degli Studi di Torino

FEDERAZIONE ORDINI FARMACISTI ITALIANI
ORDINE DEI FARMACISTI PROVINCIA DI TORINO

www.progettoappapa.it appa.onlus@unito.it
**PHASES OF A.P.P.A.® PROJECT**

**Phase «zero»**
- Preliminary pharmaco-economic study which implies a trip of the A.P.P.A.® staff on site to value the local situation and recipient areas. Some medicines should be purchased in local pharmacies and sent to the laboratory of the University of Turin to value if these medicinal products, present on the local market, respect the declared characteristics or are counterfeit.

1. Choice of the place where building the galenic lab, choice of medicines needed and of the correct pharmaceutical forms, related to the local pathologies.

2. Stage in A.P.P.A.® lab of Turin, for a Pharmacy’s student of Pharmacy Faculty of Turin; the stage leads to learn all the necessary to be able to prepare the programmed medicinal products.

3. A technician of the Country holding the lab comes to Italy to learn the procedures of galenic medicines in A.P.P.A.® lab of Turin, under a Pharmacy’s student supervision. During this period the material needed for galenic lab will be sent to local partners.

4. Training period in the chosen Country, during which the local technician, who has been in Italy to learn galenic methods and procedures, will be coordinated in his work by the Pharmacy’s student sent to the A.P.P.A.® lab.

5. Quality control of medicinal products routinely prepared in new galenic lab; moreover some sample of these are sent to University of Turin, Pharmacy Faculty, where they are tested to verify their quality.

6. Periodical stages at new lab for Pharmacy’s students of Pharmacy Faculty of Turin are performed each year both to give a continuous supervision of medicinal products prepared in the lab and to create new formulations according to the requests of medical doctors responsible of the medical centers.
WHY GALENICS IN DC?

USING LOCAL PERSONAL TEACHING THEM A JOB: AUTONOMY

ALLOWING THE SALE OF CHEAP HIGH QUALITY MEDICINES

AVOIDING THE PURCHASE OF MEDICINES ILLEGALLY IMPORTED

CUSTOMIZING THE DOSAGES AND PHARMACEUTICAL FORMS ACCORDING TO THE ACTUAL NEEDS OF PATIENTS
BASIC CONDITIONS FOR OPENING
A LAB FOR THE PREPARATION OF GALENIC MEDICINAL PRODUCTS

- HIGH PERCENTAGE OF COUNTERFEIT MEDICINES IN THE AREA
- LOCAL POOR AVAILABILITY OF QUALITY MEDICINES
- HIGH COST OF INDUSTRIAL MEDICINES
- APPROVAL OF LOCAL AUTHORITIES
The project was born from the need and the desire to teach a trade to people leaving in Developing Countries and to ensure the production of safe and effective medicines.

**AIM**

- **EASIER ACCESS TO MEDICINES**
- **DECREASE MORTALITY**
- **AFRICA: HIGH PRESENTS OF COUNTERFEIT MEDICINES**
- **NO THERAPEUTIC EFFECT**
- **CASES OF INTOXICATION**

**ENDEMIC DESEASES IN THE AREA**
- MALARIA
- SALMONELLA
- VENEREAL DESEASES
- HEPATITIS A,B,C,D,E,
- HIV
- TUBERCULOSIS
- OTHERS

**CHOICE OF THERAPEUTIC CLASSES FOR THE GALENIC LAB**
- ANTIMALARALS
- TOPICAL ANTIFUNGAL
- TOPCAL AND SYSTEMIC ANTIBIOTICIS
- SYSTEMIC AND TOPICAL NSAD
- ANTIPYRETICS
- ANTIPARASITICS (antihelmintics, antiamebic, scabicidi)
- DISINFECTIONS

**FORMULATION**

- **OINTMENT FOR SKIN APPLICATION**
- **LIQUID**
  - ORAL
  - FOR SKIN APPLICATION
- **SUPPOSITORY**
- **ORAL SOLID**

**PHARMACEUTICAL FORM**
### A.P.P.A.® LABS HANDBOOK

**SEMISOLID PREPARATIONS FOR CUTANEOUS APPLICATION**

**LIQUID PREPARATIONS FOR CUTANEOUS APPLICATION**

**SOLID PREPARATIONS**

**LIQUID PREPARATIONS FOR ORAL USE**

- Solutions
- Suspension
- Syrups
- Drops

**ORAL GEL**

**POWDER FOR ORAL USE**

**RECTAL PREPARATIONS**

**STERILE PREPARATIONS**

- Large volume parenteral solutions

---

**101 FORMULATIONS**

---

*Preparazioni sospese a periodi alterni in base alle necessità dell'ospedale.*
### SAINT DAMIEN PAEDIATRIC HOSPITAL
PORT-AU-PRINCE - HAITI

---

### HAITI: WHY?

#### MEDICINAL PRODUCTS

<table>
<thead>
<tr>
<th>LOT</th>
<th>API</th>
<th>PROVENANCE</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6C090</td>
<td>Acetazolamide 250 mg</td>
<td>Haiti</td>
<td>Unsatisfied: Uniformity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>of content (2.9.6), Friability (2.9.7)</td>
</tr>
<tr>
<td>0302609</td>
<td>Ampicillin 1g</td>
<td>India</td>
<td>Unsatisfied: Bacterial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>endotixins (2.6.14.)</td>
</tr>
<tr>
<td>071202</td>
<td>Chloramphenicol 1g</td>
<td>USA</td>
<td>Suitable</td>
</tr>
<tr>
<td>09K4840A</td>
<td>Phenobarbital 30 mg</td>
<td>Haiti</td>
<td>Unsatisfied: Friability</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(2.9.7), Hardness (2.9.8)</td>
</tr>
<tr>
<td>08E2978-A</td>
<td>Phenobarbital syrup 18mg/5ml</td>
<td>Haiti</td>
<td>Suitable</td>
</tr>
<tr>
<td>08111487</td>
<td>Propanolol 40mg</td>
<td>Brasil</td>
<td>Unsatisfied: Uniformity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>of content (2.9.6)</td>
</tr>
<tr>
<td>L08111487</td>
<td>Spironolactone 25mg</td>
<td>Domenican Republic</td>
<td>Suitable</td>
</tr>
</tbody>
</table>
PAEDIATRICS: WHY?

PREPARATION OF CAPSULES FOR CHILDREN FROM INDUSTRIAL HIGH-DOSE TABLETS

PROBLEMS:
✓ Method of preparation
✓ Quality of industrial tablets
✓ Stability of the preparations
✓ Administration of capsules for the neonatal and paediatric treatment

<table>
<thead>
<tr>
<th>LOT</th>
<th>API</th>
<th>PROVENANCE</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>200910-A</td>
<td>Acetazolamide 25 mg</td>
<td>St Damien Hospital</td>
<td>Unsatisfied: Uniformity of content (2.9.6)</td>
</tr>
<tr>
<td>A-200S10-A</td>
<td>Acetazolamide 25 mg</td>
<td>St Damien Hospital</td>
<td>Suitable</td>
</tr>
<tr>
<td>121110-B Exp</td>
<td>Captopril 1,25 mg</td>
<td>St Damien Hospital</td>
<td>Unsatisfied: Uniformity of mass (2.9.5)</td>
</tr>
<tr>
<td>230610-C</td>
<td>Phenytoin 10 mg</td>
<td>St Damien Hospital</td>
<td>Suitable</td>
</tr>
<tr>
<td>230610-G</td>
<td>Phenytoin 10 mg</td>
<td>St Damien Hospital</td>
<td>Suitable</td>
</tr>
</tbody>
</table>
In agreement with local medical doctors the drugs for the paediatric therapy are chosen and then formulated: liquid oral formulations are preferred and appropriate excipients are selected.

For each formulation a specific card (written in local language) has been prepared. The card shows the procedure of preparation and the characteristics of each component present in the formulation.

Each preparation have been tested to check its quality and its stability under different environmental conditions in accordance with the EMA guidelines.
### Préparations Pédagogiques

<table>
<thead>
<tr>
<th>Sirops</th>
<th>ACIDE ASCORBIQUE 10 mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CANREONATE DE POTASSIUM 1 mg/ml</td>
</tr>
<tr>
<td></td>
<td>FER SULFATE 5 mg/ml</td>
</tr>
<tr>
<td></td>
<td>IBUPROFENE 20 mg/ml</td>
</tr>
<tr>
<td></td>
<td>PROPRANOLOL 0,5 mg/ml</td>
</tr>
<tr>
<td></td>
<td>RANITIDINE 15 mg/ml</td>
</tr>
<tr>
<td></td>
<td>SALBUTAMOL 0,4 mg/ml</td>
</tr>
<tr>
<td></td>
<td>VITAMINE B6 1 mg/ml</td>
</tr>
</tbody>
</table>

### Solutions

<table>
<thead>
<tr>
<th>Solutions</th>
<th>CAPTOPRIL 1 mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FUROSEMIDE 1 mg/ml</td>
</tr>
</tbody>
</table>

### Gouttes

<table>
<thead>
<tr>
<th>Gouttes</th>
<th>NIFEDIPINE 1 mg/gtt</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RANITIDINE 4 mg/gtt</td>
</tr>
<tr>
<td></td>
<td>SALBUTAMOL 0,2 mg/gtt</td>
</tr>
<tr>
<td></td>
<td>VITAMINE B6 0,5 mg/gtt</td>
</tr>
</tbody>
</table>

### Suspensions

<table>
<thead>
<tr>
<th>Suspensions</th>
<th>VITAMINE B COMPLEX 5,8 mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml</td>
</tr>
</tbody>
</table>

**Préparations de Propranolol Chlorhydrate Sirope 0,5 mg/ml**

Formulation pour 100 ml:

<table>
<thead>
<tr>
<th>Ingrédients</th>
<th>Quantité</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol chlorhydrate</td>
<td>0,05 g</td>
</tr>
<tr>
<td>Carboxyméthylcellulose sodique</td>
<td>1,00 g</td>
</tr>
<tr>
<td>Sodium citrate</td>
<td>0,21 g</td>
</tr>
<tr>
<td>Acide chlorhydrate monohydraté</td>
<td>0,03 g</td>
</tr>
<tr>
<td>Eau dépurée</td>
<td>72,25 g</td>
</tr>
<tr>
<td>Nipagne sodique</td>
<td>0,07 g</td>
</tr>
<tr>
<td>Saccharose</td>
<td>3,233 g</td>
</tr>
</tbody>
</table>

**Caractéristiques chimiques physiques:**

Poudre cristalline blanche ou blanchâtre, il est inodore et avec un goût amer.
Soluible dans l'eau (1:20) et dans l'alcool (1:20).

**Propriétés pharmacologiques:**
Le propranolol a une activité β-bloquante. Il est un antagoniste compétitif des deux récepteurs β1 et β2. Non cardioselectif. Il est utilisé dans l'hypertension.

**Pharmacocinétique:**
2,5-5 mg correspondant à 5-10 ml.

**Préparation:**
1. Sublimer la naphtylodode dans l'eau dépurée.
2. Ajouter le sodium citrate et l'acide chlorhydrate monohydraté dans la solution.
3. Ajouter le propranolol chlorhydrate.
4. Ajouter la carboxyméthylcellulose sodique peu à la fois, mélanger très lentement.
5. Ajouter le saccharose.
6. Contrôler le pH. (Il ne doit pas être supérieur à 4,5).

**Instructions et contre-indications:**
Contre-indiqué pour les patients avec des maladies obstructives chroniques des voies aériennes.

**Stabilité et conservation:** Pour propranolol:
Conserver dans des récipients bien fermés, à l'abri de la lumière et de l'air.
STABILITY STUDY OF THE PREPARED LIQUID PHARMACEUTICAL FORMS

Method:

<table>
<thead>
<tr>
<th>STORAGE CONDITION</th>
<th>T (°C)</th>
<th>RH</th>
<th>PERIOD COVERED BY DATA</th>
<th>ANALYTICAL METHOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>25±2</td>
<td>60±5%</td>
<td>12 months, analysis at time zero (T0) and every 30 days (from TS-1 to TS-12)</td>
<td>UV-VIS spectrophotometric assay</td>
</tr>
<tr>
<td>Refrigerator</td>
<td>5±3</td>
<td>-</td>
<td>12 months, analysis at time zero (T0) and every 30 days (from TR-1 to TR-12)</td>
<td></td>
</tr>
<tr>
<td>Accelerated</td>
<td>40±2</td>
<td>60±5%</td>
<td>3 months, analysis at time zero (T0) and every 30 days (from TA-1 through TA-3)</td>
<td></td>
</tr>
</tbody>
</table>

EMA Guideline on stability testing: stability testing of existing active substances and related finished products, 2003, CPMP/QWP/122/02, rev 1 corr

EVALUATION OF THE EXPIRATION DATE
### STABILITY STUDY: RESULTS

<table>
<thead>
<tr>
<th>PREPARATIONS PEDIATRIQUES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SIROPS</td>
<td></td>
</tr>
<tr>
<td>ACIDE ASCORBIQUE 10 mg/ml</td>
<td></td>
</tr>
<tr>
<td>CANREONATE DE POTASSIUM 1 mg/ml</td>
<td></td>
</tr>
<tr>
<td>FER SULFATE 5 mg/ml</td>
<td></td>
</tr>
<tr>
<td>IBUPROFENE 20 mg/ml</td>
<td></td>
</tr>
<tr>
<td>PROPAANOLOL 0,5 mg/ml</td>
<td></td>
</tr>
<tr>
<td>RANITIDINE 15 mg/ml</td>
<td></td>
</tr>
<tr>
<td>SALBUTAMOL 0,4 mg/ml</td>
<td></td>
</tr>
<tr>
<td>VITAMINE B₆ 1 mg/ml</td>
<td></td>
</tr>
<tr>
<td>SOLUTIONS</td>
<td></td>
</tr>
<tr>
<td>CAPTOPRIL 1 mg/ml</td>
<td></td>
</tr>
<tr>
<td>FUROSEMIDE 1 mg/ml</td>
<td></td>
</tr>
<tr>
<td>GOUTTES</td>
<td></td>
</tr>
<tr>
<td>NIFEDIPINE 1 mg/gtt</td>
<td></td>
</tr>
<tr>
<td>RANITIDINE 4 mg/gtt</td>
<td></td>
</tr>
<tr>
<td>SALBUTAMOL 0,2 mg/gtt</td>
<td></td>
</tr>
<tr>
<td>VITAMINE B₆ 0,5 mg/gtt</td>
<td></td>
</tr>
<tr>
<td>SUSPENSIONS</td>
<td></td>
</tr>
<tr>
<td>VITAMINE B COMPLEX 5,8 mg/ml</td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml</td>
<td></td>
</tr>
</tbody>
</table>

The stability has been demonstrated for **12 MONTHS** for all formulations.

### For SIROPS:
- ACIDE ASCORBIQUE 10 mg/ml
- CANREONATE DE POTASSIUM 1 mg/ml
- FER SULFATE 5 mg/ml
- IBUPROFENE 20 mg/ml
- PROPAANOLOL 0,5 mg/ml
- RANITIDINE 15 mg/ml
- SALBUTAMOL 0,4 mg/ml
- VITAMINE B₆ 1 mg/ml

### For SOLUTIONS:
- CAPTOPRIL 1 mg/ml
- FUROSEMIDE 1 mg/ml

### For GOUTTES:
- NIFEDIPINE 1 mg/gtt
- RANITIDINE 4 mg/gtt
- SALBUTAMOL 0,2 mg/gtt
- VITAMINE B₆ 0,5 mg/gtt

### For SUSPENSIONS:
- VITAMINE B COMPLEX 5,8 mg/ml
- MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml

---

**BUT** housing and environmental conditions are **not suitable** for a proper storage of the preparations.

**VALIDITY PERIOD:** **3 MONTHS**
PAEDIATRIC FORMULATIONS: NON ONLY IN HAITI

EXTEMPORANEOUS SUSPENSION FOR ORAL USE

Total amount of solvent
each notch = 1 dosage unit

CAMEROUN

SUPPOSITORY

ANGOLA
Galenics, in accord with the European Law (Ph Eur), must guarantee “the quality as a fundamental support to the security and the efficacy”
QUALITY CONTROL AND QUALITY ASSURANCE

<table>
<thead>
<tr>
<th>ANALYSIS</th>
<th>METHOD REF.</th>
<th>ACCEPTANCE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>General aspect</td>
<td>Visual</td>
<td>Posological unit integrity</td>
</tr>
<tr>
<td>Uniformity of content</td>
<td>Ph. Eur. 7 ed. Assay 2.9.6</td>
<td>Each individual content is between 85% and 115% of the average content (10 dosage units)</td>
</tr>
</tbody>
</table>

SPECTROPHOTOMETRY UV/VIS

"...reuse, repair equipment and goods instead of throwing them in a landfill, exceeding the consumerist obsession of the obsolescence of objects and the tension to the new...”
ANGOLA – Cubal, Nossa Senhora de Paz hospital, Companhia de Santa Teresa de Jesus.
ANGOLA – Funda, A.M.E.N. ONG health care facility.
CAMEROUN – Douala, La Bethanie hospital.
CAMEROUN – Garoua, Notre Dame des Apôtres hospital, Djamboutou.
CIAD – N’Djamena, Le Bon Samaritain hospital.
HAITI – Tabarre Chateaublond, N.P.H. Saint Damien paediatric hospital.
MADAGASCAR – Vohipeno, Henintsoa hospital.
MADAGASCAR – Ihosy, Eglise Catholique Apostolique Romaine medical center.
ECONOMIC INVESTMENT IN RAW MATERIALS: $\approx 100.000$ €

ADMINISTERED DOSES:

i.e. cps $\approx 7.500.000$

A GOOD REASON TO GO ON

BUT WITH THE AIM OF

BECOME LESS AND LESS INDISPENSABLES